RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Checkmate Pharmaceuticals Stock

Checkmate Pharmaceuticals Employees 2024

Checkmate Pharmaceuticals Employees

22

Ticker

CMPI

ISIN

US1628181083

WKN

A2QAMD

In 2024, Checkmate Pharmaceuticals employed 22 people, a 0% change from the 0 number of employees in the previous year.

Checkmate Pharmaceuticals Aktienanalyse

What does Checkmate Pharmaceuticals do?

Checkmate Pharmaceuticals Inc is a biopharmaceutical company based in Cambridge, Massachusetts. It was founded in 2015 and specializes in the research and development of immuno-oncology therapies. The company has an innovative business model aimed at improving the immune response against cancer. It utilizes the natural ability of the immune system to recognize and eliminate cancer cells. Immuno-oncology is a major trend in cancer therapy today, with the goal of harnessing the body's own immune system to fight cancer cells. Checkmate Pharmaceuticals focuses on the development of unique first-in-class immunotherapeutics. The company collaborates closely with leading academic institutions and international organizations to maximize the potential of its technology and achieve the best results. The business of Checkmate Pharmaceuticals can be divided into three areas, from the Checkmate platform technology, for which multiple patents have been filed, to the two products: CMP-001 (classified as Breakthrough Therapy) and CMP-003. The Checkmate platform technology is based on stimulating immune responses through the ligation of oligonucleotides, which in turn is intended to promote the recognition and elimination of cancer cells. This method aims to safely and effectively harness the benefits of immunotherapy and successfully control the potential hazards of the immune system. CMP-001 is an immunotherapeutic currently in phase 2a clinical development. It is a combination of an adjuvant called STING agonists (also known as Sting-Signalling agonist) and a toll-like receptor-ligand of nucleotide (TLR-9), which help stimulate the body's immune system and trigger an immune response against cancer cells. CMP-001 has been granted 'Breakthrough Therapy' status by the US FDA, meaning that the drug offers a significant advancement in the treatment of patients with serious or life-threatening diseases compared to currently available therapies. CMP-003 is another development by Checkmate Pharmaceuticals, aiming to regulate excessive immune response. Along with STING, antibodies against poxviruses have been shown to activate the immune system and enable effective tumor therapy. One of the main target populations for Checkmate Pharmaceuticals is patients with various types of tumors such as melanoma, small cell lung cancer, and solid tumors that respond to immune system stimulation. Currently, the company is financed by renowned capital investors such as F-Prime Capital, HBM Healthcare Investments, and Sofinnova Investments. The company offers promising perspectives in cancer research and has the potential to deliver further advancements in the field of immuno-oncology with new products. These developments can help make cancer therapy more effective and safer, ultimately moving towards the goal of fighting cancer. Checkmate Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Checkmate Pharmaceuticals's Employee Base

Checkmate Pharmaceuticals's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Checkmate Pharmaceuticals's operational capacity and future potential.

Year-to-Year Comparison

Assessing Checkmate Pharmaceuticals's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Checkmate Pharmaceuticals's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Checkmate Pharmaceuticals’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Checkmate Pharmaceuticals stock

How many employees does Checkmate Pharmaceuticals have this year?

Checkmate Pharmaceuticals has 22 undefined employees this year.

How many employees did Checkmate Pharmaceuticals have compared to the previous year?

Compared to the previous year, Checkmate Pharmaceuticals had 0% more employees.

What impact did the number of employees have on the company Checkmate Pharmaceuticals?

The number of employees has a direct impact on the efficiency and productivity of Checkmate Pharmaceuticals. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Checkmate Pharmaceuticals?

The number of employees can also have an impact on investors of Checkmate Pharmaceuticals, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Checkmate Pharmaceuticals affect the company?

An increase in equity of Checkmate Pharmaceuticals can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Checkmate Pharmaceuticals's equity affect the company?

A reduction in equity of Checkmate Pharmaceuticals can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Checkmate Pharmaceuticals?

Some factors that can influence the equity of Checkmate Pharmaceuticals include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Checkmate Pharmaceuticals so important for investors?

The equity of Checkmate Pharmaceuticals is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Checkmate Pharmaceuticals influence the company?

The number of employees at Checkmate Pharmaceuticals can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Checkmate Pharmaceuticals evolved in recent years?

In recent years, the number of employees at Checkmate Pharmaceuticals has changed by NaN.

How many employees does Checkmate Pharmaceuticals currently have?

Checkmate Pharmaceuticals currently has 22 undefined employees.

Why is the number of employees important for investors of Checkmate Pharmaceuticals?

The number of employees is important for investors of Checkmate Pharmaceuticals as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Checkmate Pharmaceuticals take to change the number of employees?

To change the number of employees, Checkmate Pharmaceuticals can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Checkmate Pharmaceuticals pay?

Over the past 12 months, Checkmate Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Checkmate Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Checkmate Pharmaceuticals?

The current dividend yield of Checkmate Pharmaceuticals is .

When does Checkmate Pharmaceuticals pay dividends?

Checkmate Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Checkmate Pharmaceuticals?

Checkmate Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Checkmate Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Checkmate Pharmaceuticals located?

Checkmate Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Checkmate Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Checkmate Pharmaceuticals from 9/7/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/7/2024.

When did Checkmate Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/7/2024.

What was the dividend of Checkmate Pharmaceuticals in the year 2023?

In the year 2023, Checkmate Pharmaceuticals distributed 0 USD as dividends.

In which currency does Checkmate Pharmaceuticals pay out the dividend?

The dividends of Checkmate Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Checkmate Pharmaceuticals

Our stock analysis for Checkmate Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Checkmate Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.